StockTalk is a Stockhead video series featuring a roundtable of experts discussing a new investment topic each week. In this edition, host Dr Nigel Finch discusses cancer treatment through the use of CAR T cell therapy.

Populating the expert panel this week is Jennifer Chow, COO of Chimeric Therapeutics (ASX:CHM) and Steven Yatomi-Clarke CEO, Prescient Therapeutics (ASX:PTX).

Chimeric grabbed headlines in January 2021, following news it easily achieved its IPO fundraising target of $35m.

Prescient also featured in a recent Stockhead article looking at its choice of three cancer programs for its next-generation CAR T platform.

The group discusses a range of topics, including how both companies began developing CAR T cell therapies, the tumour types being targeted, timescales towards strong revenue, research plans for the year ahead and much more.

So click above to tune in. 

 

Read MoreAusbiotechBiotechDrug Development

You might be interested in